NEW YORK – Sydney, Australia-based SpeeDx and Utrecht, Netherlands-based MolGen have formed a supply and distribution partnership, the firms announced Wednesday.
The collaboration agreement covers the supply and distribution of clinical diagnostics products and instruments in Europe and the Asia-Pacific region and leverages the existing infrastructure of the two companies. It combines MolGen's liquid handling and purpose-built automation with SpeeDx's COVID-19 diagnostic solutions, extending a full workflow offering to pathology laboratories, the firms said.
Specifically, MolGen has developed a nucleic acid extraction portfolio called PurePrep, liquid handling instrumentation, and purpose-built automation to facilitate high-volume testing of SARS-CoV-2. SpeeDx, meanwhile, developed a CE-IVD-marked SARS-CoV-2 test based on the firm's proprietary PlexPCR technology.
"Our DNA and RNA extraction solutions and automated workflow perfectly pair with SpeeDx diagnostic assay technology," said Maarten de Groot, MolGen's CEO. "During the COVID pandemic, adding the [SpeeDx] CE-IVD SARS-CoV-2 assay to our diagnostics portfolio is [a] great opportunity to start our collaboration. And this is only the beginning of jointly building an innovative product portfolio," he added.